Is Paclitaxel-Eluting Stent Use Justified by an Adequate Risk Profile?

JACC Cardiovasc Interv. 2021 Mar 22;14(6):702-703. doi: 10.1016/j.jcin.2021.02.015.
No abstract available

Keywords: DCB; DES; paclitaxel; vessel aneurysm; vessel degeneration.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Coronary Restenosis*
  • Drug-Eluting Stents*
  • Humans
  • Paclitaxel / adverse effects
  • Stents
  • Treatment Outcome

Substances

  • Paclitaxel